Exentis enables large-scale production of innovative tablets

With its 3D cold printing process, Exentis Group AG enables the greatest production volumes of tablets with customizable active ingredient delivery profiles. This is the finding of an industry study by the management consultancy Roland Berger. Exentis is the leading provider of a 3D technology platform for industrialized additive manufacturing. It enables clean room applications such as tablets or even industrial parts to be manufactured millions of times over on one 3D production system. Exentis' strategic business areas are Pharma & Medtech, New Energy and Ultra-fine Structures.

The tablets produced with Exentis' 3D technology are special because their active ingredient delivery profile can be freely adjusted in the human body. This leads to more efficient drug delivery and greater comfort during ingestion, according to the study. As well as human medicine, areas of application include veterinary medicine and nutritional supplements.

These innovative tablets can be used for medical indications in the field of neurology with epilepsy, Parkinson's disease or migraine; in endocrinology with diabetes; and in cardiology, oncology and psychiatry. In terms of key indications, the experts identified a market potential of well over 100 billion Swiss francs and a growth forecast of around 7 per cent annually until 2026.

The New York-based company Laxxon Medical, which has been a member of the Exentis 3D Community since 2017, has acquired an exclusive global license from Exentis for the development, production and commercialization of drugs manufactured using Exentis technology. Laxxon Medical has already granted several sublicenses for individual indications or active ingredients to renowned US pharmaceutical companies. In March 2023, Laxxon concluded a long-term strategic cooperation agreement with Hovione, a leading producer in the pharmaceutical industry. ce/yvh